About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

379188 studies
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 07/24/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create an Account

  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Our Science

ozanimod (S1P1 and S1P5 Modulator)

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


Proposed Mechanism of Action

Ozanimod is an oral, sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The exact mechanism by which ozanimod exerts its therapeutic action is unknown. Preclinical data showed that ozanimod was able to induce internalization of the S1P1 receptor and decrease circulation of pro-inflammatory lymphocytes in the bloodstream. A reduction in circulating pro-inflammatory lymphocytes may prevent their migration to sites of inflammation. Preclinical data have also demonstrated that ozanimod treatment results in a dose-dependent reduction in key lymphocyte populations that play a role in inflammatory bowel disease (IBD).1 These results may support the hypothesis that S1P1 is a potential new target for IBD treatment.

Ozanimod Proposed Mechanism of Action

GI, gastrointestinal; S1P, sphingosine-1-phosphate

Ozanimod, an S1P1 and S1P5 ?modulator is hypothesized to prevent migration of lymphocytes from the lymphoid tissue to the gastrointestinal tract1